Susquehanna International Group’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $271K | Sell |
67,816
-883,527
| -93% | -$3.53M | ﹤0.01% | 5177 |
|
|
2025
Q1 | $3.03M | Sell |
951,343
-63,740
| -6% | -$203K | ﹤0.01% | 1767 |
|
|
2024
Q4 | $5.43M | Buy |
1,015,083
+796,121
| +364% | +$4.26M | ﹤0.01% | 1041 |
|
|
2024
Q3 | $1.16M | Buy |
218,962
+193,312
| +754% | +$1.02M | ﹤0.01% | 2490 |
|
|
2024
Q2 | $46.7K | Sell |
25,650
-79,376
| -76% | -$144K | ﹤0.01% | 5289 |
|
|
2024
Q1 | $187K | Sell |
105,026
-115,270
| -52% | -$205K | ﹤0.01% | 4718 |
|
|
2023
Q4 | $388K | Buy |
220,296
+92,328
| +72% | +$162K | ﹤0.01% | 4200 |
|
|
2023
Q3 | $187K | Sell |
127,968
-67,284
| -34% | -$98.2K | ﹤0.01% | 4585 |
|
|
2023
Q2 | $447K | Buy |
195,252
+184,809
| +1,770% | +$423K | ﹤0.01% | 3767 |
|
|
2023
Q1 | $9.5K | Buy |
+10,443
| New | +$9.5K | ﹤0.01% | 5731 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6229 |
|
|
2022
Q2 | – | Sell |
-48,283
| Closed | -$79K | – | 5938 |
|
|
2022
Q1 | $79K | Sell |
48,283
-27,435
| -36% | -$44.9K | ﹤0.01% | 5202 |
|
|
2021
Q4 | $182K | Sell |
75,718
-12,579
| -14% | -$30.2K | ﹤0.01% | 5010 |
|
|
2021
Q3 | $427K | Buy |
88,297
+52,591
| +147% | +$254K | ﹤0.01% | 3901 |
|
|
2021
Q2 | $95K | Sell |
35,706
-55,532
| -61% | -$148K | ﹤0.01% | 5074 |
|
|
2021
Q1 | $281K | Buy |
91,238
+75,557
| +482% | +$233K | ﹤0.01% | 4429 |
|
|
2020
Q4 | $56K | Buy |
+15,681
| New | +$56K | ﹤0.01% | 4601 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 4495 |
|
|
2020
Q2 | – | Sell |
-117,606
| Closed | -$248K | – | 4335 |
|
|
2020
Q1 | $248K | Buy |
117,606
+49,700
| +73% | +$105K | ﹤0.01% | 3607 |
|
|
2019
Q4 | $369K | Buy |
+67,906
| New | +$369K | ﹤0.01% | 2957 |
|